sur GENSIGHT BIOLOGICS S.A. (EPA:SIGHT)
Financial position of GenSight Biologics as of September 30, 2026
GenSight Biologics reported cash and cash equivalents of €0.7 million as of September 30, 2026, down from €1.7 million as of June 30. The exemption access programs generated €1.7 million in revenue in the third quarter, contributing to a total of €8.2 million since their inception. This decrease in cash is due to the summer pause in treatments and investments in manufacturing technology transfer and preparation for the RECOVER study.
Despite these inflows, the company anticipates a funding requirement of approximately €16 million, primarily for the Phase III RECOVER trial. Bridge financing or additional treatments are being considered to extend resources until March 2027.
R. E.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de GENSIGHT BIOLOGICS S.A.